Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
Oliva EN, Platzbecker U, Garcia-Manero G, Mufti GJ, Santini V, Sekeres MA, Komrokji RS, Shetty JK, Tang D, Guo S, Liao W, Zhang G, Ha X, Ito R, Lord-Bessen J, Backstrom JT, Fenaux P. Oliva EN, et al. Among authors: guo s. J Clin Med. 2021 Dec 22;11(1):27. doi: 10.3390/jcm11010027. J Clin Med. 2021. PMID: 35011768 Free PMC article.
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.
Santini V, Almeida A, Giagounidis A, Platzbecker U, Buckstein R, Beach CL, Guo S, Altincatal A, Wu C, Fenaux P. Santini V, et al. Among authors: guo s. Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):136-144.e7. doi: 10.1016/j.clml.2017.12.004. Epub 2017 Dec 30. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29429612 Free article. Clinical Trial.
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
Mesa RA, Schaap N, Vannucchi AM, Kiladjian JJ, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Rose S, Abraham P, Lord-Bessen J, Tang D, Guo S, Ye X, Harrison CN. Mesa RA, et al. Among authors: guo s. Hemasphere. 2021 Apr 29;5(5):e553. doi: 10.1097/HS9.0000000000000553. eCollection 2021 May. Hemasphere. 2021. PMID: 33969273 Free PMC article.
Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Jourdan E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Verstovsek S, Tang D, Abraham P, Lord-Bessen J, Rose S, Guo S, Liao W, Mesa RA. Harrison CN, et al. Among authors: guo s. Hemasphere. 2021 Apr 29;5(5):e562. doi: 10.1097/HS9.0000000000000562. eCollection 2021 May. Hemasphere. 2021. PMID: 33969275 Free PMC article.
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia.
Taher AT, Musallam KM, Viprakasit V, Kattamis A, Lord-Bessen J, Yucel A, Guo S, Pelligra C, Shields AL, Shetty JK, Miteva D, Bueno LM, Cappellini MD. Taher AT, et al. Among authors: guo s. BMJ Open. 2023 Mar 22;13(3):e066683. doi: 10.1136/bmjopen-2022-066683. BMJ Open. 2023. PMID: 36948565 Free PMC article. Clinical Trial.
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Cappellini MD, Taher AT, Piga A, Shah F, Voskaridou E, Viprakasit V, Porter JB, Hermine O, Neufeld EJ, Thompson AA, Tang D, Yucel A, Lord-Bessen J, Yu P, Guo S, Shetty JK, Miteva D, Zinger T, Backstrom JT, Oliva EN. Cappellini MD, et al. Among authors: guo s. Eur J Haematol. 2023 Jul;111(1):113-124. doi: 10.1111/ejh.13975. Epub 2023 Apr 24. Eur J Haematol. 2023. PMID: 37095595 Clinical Trial.
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
Schadendorf D, Tawbi H, Lipson EJ, Stephen Hodi F, Rutkowski P, Gogas H, Lao CD, Grob JJ, Moshyk A, Lord-Bessen J, Hamilton M, Guo S, Shi L, Keidel S, Long GV. Schadendorf D, et al. Among authors: guo s. Eur J Cancer. 2023 Jul;187:164-173. doi: 10.1016/j.ejca.2023.03.014. Epub 2023 Mar 22. Eur J Cancer. 2023. PMID: 37167764 Free article. Clinical Trial.
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Roussel M, Hebraud B, Hulin C, Perrot A, Caillot D, Stoppa AM, Macro M, Escoffre M, Arnulf B, Belhadj K, Karlin L, Garderet L, Facon T, Guo S, Weng J, Dhanasiri S, Leleu X, Moreau P, Attal M. Roussel M, et al. Among authors: guo s. Leuk Lymphoma. 2020 Jun;61(6):1323-1333. doi: 10.1080/10428194.2020.1719091. Epub 2020 Feb 22. Leuk Lymphoma. 2020. PMID: 32090636
Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial.
Witjes JA, Galsky MD, Gschwend JE, Broughton E, Braverman J, Nasroulah F, Maira-Arce M, Ye X, Shi L, Guo S, Hamilton M, Bajorin DF. Witjes JA, et al. Among authors: guo s. Eur Urol Oncol. 2022 Oct;5(5):553-563. doi: 10.1016/j.euo.2022.02.003. Epub 2022 Mar 11. Eur Urol Oncol. 2022. PMID: 35288066 Free PMC article. Clinical Trial.
14,552 results
You have reached the last available page of results. Please see the User Guide for more information.